AbbVie
ABBV
#27
Rank
$282.28 B
Marketcap
$159.62
Share price
0.14%
Change (1 day)
37.00%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

P/E ratio for AbbVie (ABBV)

P/E ratio as of November 2022 (TTM): 21.1

According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.12. At the end of 2021 the company had a P/E ratio of 20.7.

P/E ratio history for AbbVie from 2013 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202120.7-42.97%
202036.3118.84%
201916.6-34.15%
201825.2-13.12%
201729.070.73%
201617.0-9.1%
201518.7-68.14%
201458.7189.17%
201320.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
9.20-56.44%๐Ÿ‡บ๐Ÿ‡ธ USA
55.8 164.23%๐Ÿ‡บ๐Ÿ‡ธ USA
22.6 7.01%๐Ÿ‡บ๐Ÿ‡ธ USA
15.5-26.58%๐Ÿ‡บ๐Ÿ‡ธ USA
32.1 52.05%๐Ÿ‡บ๐Ÿ‡ธ USA
25.4 20.04%๐Ÿ‡บ๐Ÿ‡ธ USA
-157-845.40%๐Ÿ‡ฌ๐Ÿ‡ง UK
4.26-79.82%๐Ÿ‡ฌ๐Ÿ‡ง UK
200 848.13%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.